期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 188, 期 1, 页码 77-85出版社
WILEY
DOI: 10.1111/bjh.16362
关键词
minimal residual disease; acute myeloid leukaemia; genetics; measurable residual disease; mutation detection; myeloid leukaemia
类别
资金
- Intramural Research Program of the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL006163] Funding Source: NIH RePORTER
Acute myeloid leukaemia (AML) is a blood cancer characterized by acquired genetic mutations. There is great interest in accurately establishing measurable residual disease (MRD) burden in AML patients in remission after treatment but at risk of relapse. However, inter- and intrapatient genetic diversity means that, unlike in the chronic myeloid and acute promyelocytic leukaemias, no single genetic abnormality is pathognomonic for all cases of AML MRD. Next-generation sequencing offers the opportunity to test broadly and deeply for potential genetic evidence of residual AML, and while not currently accepted for such use clinically, is likely to be increasingly used for AML MRD testing in the future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据